Royal Bank of Canada Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Royal Bank of Canada on February 8, 2012, for the month of February 2012. The filing serves to incorporate by reference exhibits related to the issuance of Senior Global Medium-Term Notes, Series E, pursuant to the Bank's shelf registration statement on Form F-3 (File No. 333-171806).
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt levels, or liquidity ratios. The document focuses exclusively on the terms of specific securities issuances.
Material Changes and Securities Issuance
The Bank issued four distinct series of structured notes with a total principal amount of approximately $21.87 million. The details are as follows:
- Leveraged Buffered Equity Index-Linked Notes: Linked to the S&P 500 Index, due August 8, 2013. Principal amount: $2,025,000.
- Airbag Yield Optimization Notes: Linked to a single common stock. Principal amount: $6,780,000.
- Trigger Yield Optimization Securities: Linked to a single common equity security. Principal amount: $8,817,393.36.
- Direct Investment Notes: Linked to the EquityCompass Equity Risk Management Strategy, due March 8, 2013. Principal amount: $4,250,000.
All securities were priced between February 1 and February 3, 2012, with settlement occurring on February 8, 2012.
Guidance, Risks, and Legal Opinions
The filing includes legal opinions regarding the validity of the Notes under Canadian, Ontario, and Quebec law (Norton Rose Canada LLP) and New York law (Morrison & Foerster LLP). No management commentary, forward-looking guidance, or specific risk factors beyond the inherent nature of the structured products are provided in this text.
Investor Verification Checklist
- Verify the specific underlying assets and payoff structures for the "Airbag" and "Trigger" yield optimization notes, as these are complex derivatives.
- Confirm the credit rating of Royal Bank of Canada at the time of issuance to assess counterparty risk.
- Review the full Pricing Supplements referenced in the filing for detailed terms regarding leverage, buffers, and triggers.
- Check subsequent filings to ensure no superseding documents have altered the terms of these notes.